A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 01 Dec 2023
At a glance
- Drugs IBI-334 (Primary)
- Indications Carcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Innovent Biologics
Most Recent Events
- 21 Nov 2023 Phase of the study is changed from phase 1 to phase 1/2.
- 20 Oct 2023 The protocol has been amended to increase in number of Arms by 6 from single arm with change in Allocation to Randomized.
- 20 Oct 2023 Status changed from not yet recruiting to recruiting.